CoChat
Sign Up
Cited by 67

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies

Rocamora, Frances, Peralta, Angelo G., Shin, Seunghyeon, Sorrentino, James, Wu, Mina Ying Min, Toth, Eric A., Fuerst, Thomas R., Lewis, Nathan E.·2023·Biotechnology Advances
DOI 10.1016/j.biotechadv.2023.108206
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biotechadv.2023.108206

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 358

  1. Achord, 1978, Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells, Cell, 15, 269, 10.1016/0092-8674(78)90102-2 · DOI
  2. Altman, 2019, Absence of Neu5Gc and presence of anti-Neu5Gc antibodies in humans-an evolutionary perspective, Front. Immunol., 10, 789, 10.3389/fimmu.2019.00789 · DOI · Paper page
  3. Amon, 2017, Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy, Oncotarget, 8, 112236, 10.18632/oncotarget.23096 · DOI
  4. Andre, 1997, Bioconjug. Chem., 8, 845, 10.1021/bc970164d · DOI
  5. Andre, 2004, Determination of modulation of ligand properties of synthetic complex-type biantennary N-glycans by introduction of bisecting GlcNAc in silico, in vitro and in vivo, Eur. J. Biochem., 271, 118, 10.1046/j.1432-1033.2003.03910.x · DOI
  6. Andresen, 2012, 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation, J. Immunol., 188, 1847, 10.4049/jimmunol.1004085 · DOI
  7. Anobile, 1998, Glycoform composition of serum gonadotrophins through the normal menstrual cycle and in the post-menopausal state, Mol. Hum. Reprod., 4, 631, 10.1093/molehr/4.7.631 · DOI
  8. Anthony, 2010, A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs, J. Clin. Immunol., 30, S9, 10.1007/s10875-010-9405-6 · DOI
  9. Aoyama, 2019, Effects of terminal galactose residues in mannose alpha1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies, MAbs, 11, 826, 10.1080/19420862.2019.1608143 · DOI
  10. Arico, 2013, N-glycosylation humanization for production of therapeutic recombinant glycoproteins in Saccharomyces cerevisiae, Glycosylation Eng. Biopharm. Methods Protoc., 2013, 45, 10.1007/978-1-62703-327-5_4 · DOI
  11. Ashwell, 1974, The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins, Adv. Enzymol. Relat. Areas Mol. Biol., 41, 99, 10.1002/9780470122860.ch3 · DOI
  12. Bakowski, 2022, Evolution of complexity in non-viral oligonucleotide delivery systems: from gymnotic delivery through bioconjugates to biomimetic nanoparticles, RNA Biol., 19, 1256, 10.1080/15476286.2022.2147278 · DOI
  13. Barton, 1991, Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher’s disease, N. Engl. J. Med., 324, 1464, 10.1056/NEJM199105233242104 · DOI
  14. Basile, 2018, Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase, J. Control. Release, 269, 15, 10.1016/j.jconrel.2017.10.043 · DOI
  15. Baudys, 1995, Physical stabilization of insulin by glycosylation, J. Pharm. Sci., 84, 28, 10.1002/jps.2600840108 · DOI
  16. Beck, 2010, GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins, Expert Opin. Drug Discovery, 5, 95, 10.1517/17460440903413504 · DOI
  17. Behrens, 2016, Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein, Cell Rep., 14, 2695, 10.1016/j.celrep.2016.02.058 · DOI
  18. Berthe, 2003, Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas, Eur. J. Cancer, 39, 635, 10.1016/S0959-8049(02)00627-5 · DOI
  19. Bocci, 1989, Catabolism of therapeutic proteins and peptides with implications for drug delivery, Adv. Drug Deliv. Rev., 4, 149, 10.1016/0169-409X(89)90017-3 · DOI
  20. Bonam, 2019, Lysosomes as a therapeutic target, Nat. Rev. Drug Discov., 18, 923, 10.1038/s41573-019-0036-1 · DOI
  21. Bonetti, 1994, Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha, J. Hepatol., 20, 416, 10.1016/S0168-8278(94)80018-9 · DOI
  22. Bost, 2021, Delivery of oligonucleotide therapeutics: chemical modifications, lipid nanoparticles, and extracellular vesicles, ACS Nano, 15, 13993, 10.1021/acsnano.1c05099 · DOI
  23. Boyd, 1995, The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H, Mol. Immunol., 32, 1311, 10.1016/0161-5890(95)00118-2 · DOI · Paper page
  24. Brady, 1965, Metabolism of Glucocerebrosides. Ii. Evidence of an enzymatic deficiency in Gaucher’s disease, Biochem. Biophys. Res. Commun., 18, 221, 10.1016/0006-291X(65)90743-6 · DOI
  25. Brady, 1966, Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease, J. Clin. Invest., 45, 1112, 10.1172/JCI105417 · DOI
  26. Brady, 2015, The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development, MAbs, 7, 562, 10.1080/19420862.2015.1016692 · DOI
  27. Bulcha, 2021, Viral vector platforms within the gene therapy landscape, Signal Transduct. Target Ther., 6, 53, 10.1038/s41392-021-00487-6 · DOI · Paper page
  28. Bull, 2018, Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity, Cancer Res., 78, 3574, 10.1158/0008-5472.CAN-17-3376 · DOI
  29. Butler, 2014, The choice of mammalian cell host and possibilities for glycosylation engineering, Curr. Opin. Biotechnol., 30, 107, 10.1016/j.copbio.2014.06.010 · DOI · Paper page
  30. Cadaoas, 2020, Vestronidase alfa: recombinant human beta-glucuronidase as an enzyme replacement therapy for MPS VII, Mol. Genet. Metab., 130, 65, 10.1016/j.ymgme.2020.02.009 · DOI
  31. Campbell, 1984, A dominant mutation to ricin resistance in Chinese hamster ovary cells induces UDP-GlcNAc:glycopeptide beta-4-N-acetylglucosaminyltransferase III activity, J. Biol. Chem., 259, 13370, 10.1016/S0021-9258(18)90704-0 · DOI
  32. Carter, 2004, The significance of carbohydrates on G-CSF: differential sensitivity of G-CSFs to human neutrophil elastase degradation, J. Leukoc. Biol., 75, 515, 10.1189/jlb.0803378 · DOI
  33. Casadevall, 2002, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin, N. Engl. J. Med., 346, 469, 10.1056/NEJMoa011931 · DOI
  34. Ceaglio, 2008, Novel long-lasting interferon alpha derivatives designed by glycoengineering, Biochimie, 90, 437, 10.1016/j.biochi.2007.10.013 · DOI
  35. Ceaglio, 2010, Highly glycosylated human alpha interferon: an insight into a new therapeutic candidate, J. Biotechnol., 146, 74, 10.1016/j.jbiotec.2009.12.020 · DOI
  36. Chan, 2010, Therapeutic antibodies for autoimmunity and inflammation, Nat. Rev. Immunol., 10, 301, 10.1038/nri2761 · DOI
  37. Chen, 2005, Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors, Hum. Gene Ther., 16, 235, 10.1089/hum.2005.16.235 · DOI
  38. Chen, 2009, Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease, J. Pediatr., 155
  39. Chen, 2014, Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections, Proc. Natl. Acad. Sci. U. S. A., 111, 2476, 10.1073/pnas.1323954111 · DOI
  40. Chen, 2020, Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export, Oncoimmunology, 9, 1831153, 10.1080/2162402X.2020.1831153 · DOI
  41. Chen, 2022, Impact of N-linked glycosylation on therapeutic proteins, Molecules, 27, 10.3390/molecules27248859 · DOI
  42. Choi, 2019, Mannose-modified serum exosomes for the elevated uptake to murine dendritic cells and lymphatic accumulation, Macromol. Biosci., 19, 10.1002/mabi.201900042 · DOI
  43. Chung, 2008, Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose, N. Engl. J. Med., 358, 1109, 10.1056/NEJMoa074943 · DOI · Paper page
  44. Clarke, 2009, Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I, Pediatrics, 123, 229, 10.1542/peds.2007-3847 · DOI
  45. Dammen-Brower, 2022, Strategies for glycoengineering therapeutic proteins, Front. Chem., 10, 10.3389/fchem.2022.863118 · DOI
  46. Darlington, 2005, Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation, J. Immunol., 175, 996, 10.4049/jimmunol.175.2.996 · DOI
  47. De Bousser, 2023, N-glycosylation engineering in chimeric antigen receptor T cells enhances anti-tumor activity, bioRxiv
  48. De Haij, 2010, In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling, Cancer Res., 70, 3209, 10.1158/0008-5472.CAN-09-4109 · DOI
  49. Dekkers, 2017, Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities, Front. Immunol., 8, 877, 10.3389/fimmu.2017.00877 · DOI
  50. Dhar, 2019, From “serum sickness” to “Xenosialitis”: past, present, and future significance of the non-human sialic acid Neu5Gc, Front. Immunol., 10, 807, 10.3389/fimmu.2019.00807 · DOI
  51. Di Mario, 1986, Immunogenicity of biosynthetic human insulin. Humoral immune response in diabetic patients beginning insulin treatment and in patients previously treated with other insulins, Diabetes Res. Clin. Pract., 2, 317, 10.1016/S0168-8227(86)80068-7 · DOI
  52. Doebber, 1982, Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase, J. Biol. Chem., 257, 2193, 10.1016/S0021-9258(18)34905-6 · DOI
  53. Dornelles, 2017, Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis, PLoS One, 12, 10.1371/journal.pone.0184065 · DOI
  54. Douglas, 1993, Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM, Dig. Dis. Sci., 38, 601, 10.1007/BF01316787 · DOI
  55. Edgar, 2021, Sialic acid ligands of CD28 suppress costimulation of T cells, ACS Cent Sci., 7, 1508, 10.1021/acscentsci.1c00525 · DOI
  56. Egrie, 2001, Development and characterization of novel erythropoiesis stimulating protein (NESP), Br. J. Cancer, 84, 3, 10.1054/bjoc.2001.1746 · DOI
  57. Ehrenpreis, 2017, Pharmacokinetic effects of antidrug antibodies occurring in healthy subjects after a single dose of intravenous infliximab, Drugs R D, 17, 607, 10.1007/s40268-017-0211-y · DOI
  58. Elliott, 1996, Isolation and characterization of conformation sensitive antierythropoietin monoclonal antibodies: effect of disulfide bonds and carbohydrate on recombinant human erythropoietin structure, Blood, 87, 2714, 10.1182/blood.V87.7.2714.bloodjournal8772714 · DOI
  59. Elliott, 2004, Control of rHuEPO biological activity: the role of carbohydrate, Exp. Hematol., 32, 1146, 10.1016/j.exphem.2004.08.004 · DOI
  60. Farrell, 2012, Development of resistance to biologic therapies with reference to IFN-beta, Rheumatology (Oxford), 51, 590, 10.1093/rheumatology/ker445 · DOI
  61. Feins, 2019, An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer, Am. J. Hematol., 94, S3, 10.1002/ajh.25418 · DOI · Paper page
  62. Fenouillet, 1994, Functions of HIV envelope glycans, Trends Biochem. Sci., 19, 65, 10.1016/0968-0004(94)90034-5 · DOI
  63. Fernandes, 2001, The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics, Int. J. Pharm., 217, 215, 10.1016/S0378-5173(01)00603-2 · DOI
  64. Fiedler, 2018, Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas, ESMO Open, 3, 10.1136/esmoopen-2017-000303 · DOI
  65. Filipe, 2014, In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice, Pharm. Res., 31, 216, 10.1007/s11095-013-1154-9 · DOI · Paper page
  66. Fineberg, 1983, Immunogenicity of recombinant DNA human insulin, Diabetologia, 25, 465, 10.1007/BF00284452 · DOI
  67. Flintegaard, 2010, N-glycosylation increases the circulatory half-life of human growth hormone, Endocrinology, 151, 5326, 10.1210/en.2010-0574 · DOI
  68. Flynn, 2010, Naturally occurring glycan forms of human immunoglobulins G1 and G2, Mol. Immunol., 47, 2074, 10.1016/j.molimm.2010.04.006 · DOI
  69. Fossa, 1992, Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies, Int. J. Cancer, 50, 868, 10.1002/ijc.2910500606 · DOI
  70. Fox, 2015, First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient, Mol. Genet. Metab., 114, 203, 10.1016/j.ymgme.2014.10.017 · DOI
  71. Friedman, 1999, A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease, Blood, 93, 2807, 10.1182/blood.V93.9.2807.409k08_2807_2816 · DOI
  72. Fukuda, 1989, Survival of recombinant erythropoietin in the circulation: the role of carbohydrates, Blood, 73, 84, 10.1182/blood.V73.1.84.84 · DOI
  73. Furbish, 1981, Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation, Biochim. Biophys. Acta, 673, 425, 10.1016/0304-4165(81)90474-8 · DOI
  74. Futerman, 2004, The cell biology of lysosomal storage disorders, Nat. Rev. Mol. Cell Biol., 5, 554, 10.1038/nrm1423 · DOI
  75. Galili, 1988, Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora, Infect. Immun., 56, 1730, 10.1128/iai.56.7.1730-1737.1988 · DOI
  76. Garcia, 2007, Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II, Mol. Genet. Metab., 91, 183, 10.1016/j.ymgme.2007.03.003 · DOI
  77. Garcia-Garcia, 2021, FUT8-directed core fucosylation of N-glycans is regulated by the glycan structure and protein environment, ACS Catal., 11, 9052, 10.1021/acscatal.1c01698 · DOI
  78. Garg, 2006, Reduced hematopoietic toxicity, enhanced cellular uptake and altered pharmacokinetics of azidothymidine loaded galactosylated liposomes, J. Drug Target., 14, 1, 10.1080/10611860500525370 · DOI
  79. Ghaderi, 2010, Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins, Nat. Biotechnol., 28, 863, 10.1038/nbt.1651 · DOI · Paper page
  80. Goetze, 2011, High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans, Glycobiology, 21, 949, 10.1093/glycob/cwr027 · DOI · Paper page
  81. Goh, 2018, Impact of host cell line choice on glycan profile, Crit. Rev. Biotechnol., 38, 851, 10.1080/07388551.2017.1416577 · DOI
  82. Golay, 2022, Role of Fc core fucosylation in the effector function of IgG1 antibodies, Front. Immunol., 13, 10.3389/fimmu.2022.929895 · DOI
  83. Grabowski, 1995, Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources, Ann. Intern. Med., 122, 33, 10.7326/0003-4819-122-1-199501010-00005 · DOI
  84. Grabowski, 2014, Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology, Mol. Genet. Metab., 112, 1, 10.1016/j.ymgme.2014.02.011 · DOI
  85. Grigorian, 2007, Control of T cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis, J. Biol. Chem., 282, 20027, 10.1074/jbc.M701890200 · DOI
  86. Guan, 2018, Chemically precise glycoengineering improves human insulin, ACS Chem. Biol., 13, 73, 10.1021/acschembio.7b00794 · DOI
  87. Gudelj, 2018, Immunoglobulin G glycosylation in aging and diseases, Cell. Immunol., 333, 65, 10.1016/j.cellimm.2018.07.009 · DOI
  88. Halbert, 2001, Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors, J. Virol., 75, 6615, 10.1128/JVI.75.14.6615-6624.2001 · DOI
  89. Handa, 2000, Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors, J. Gen. Virol., 81, 2077, 10.1099/0022-1317-81-8-2077 · DOI
  90. Harmatz, 2004, Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), J. Pediatr., 144, 574, 10.1016/j.jpeds.2004.03.018 · DOI
  91. Harmatz, 2005, Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study, Acta Paediatr. Suppl., 94, 61
  92. Harmatz, 2006, J. Pediatr., 148, 533, 10.1016/j.jpeds.2005.12.014 · DOI
  93. Harmatz, 2018, A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease, Mol. Genet. Metab., 123, 488, 10.1016/j.ymgme.2018.02.006 · DOI
  94. Hart, 2017, Human cell line-derived monoclonal IgA antibodies for cancer immunotherapy, Bioengineering (Basel), 4
  95. Hatfield, 2022, Specific location of galactosylation in an afucosylated antiviral monoclonal antibody affects its FcgammaRIIIA binding affinity, Front. Immunol., 13, 10.3389/fimmu.2022.972168 · DOI
  96. Hebert, 2006, Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development, Biosci. Rep., 26, 7, 10.1007/s10540-006-9002-3 · DOI
  97. Hendriksz, 2014, Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study, J. Inherit. Metab. Dis., 37, 979, 10.1007/s10545-014-9715-6 · DOI
  98. Hendriksz, 2018, Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment, Mol. Genet. Metab., 123, 479, 10.1016/j.ymgme.2018.02.011 · DOI
  99. Hiatt, 2014, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy, Proc. Natl. Acad. Sci. U. S. A., 111, 5992, 10.1073/pnas.1402458111 · DOI
  100. Hirobe, 2022, The effects of chimeric antigen receptor (CAR) hinge domain post-translational modifications on CAR-T cell activity, Int. J. Mol. Sci., 23, 10.3390/ijms23074056 · DOI
  101. Houde, 2010, Post-translational modifications differentially affect IgG1 conformation and receptor binding, Mol. Cell. Proteomics, 9, 1716, 10.1074/mcp.M900540-MCP200 · DOI
  102. Huang, 2021, FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer, Nat. Commun., 12, 2672, 10.1038/s41467-021-22618-x · DOI
  103. Huang, 2022, Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models, Sci. Transl. Med., 14, eabm0899, 10.1126/scitranslmed.abm0899 · DOI
  104. Hubbard, 1979, An electron microscope autoradiographic study of the carbohydrate recognition systems in rat liver. II. Intracellular fates of the 125I-ligands, J. Cell Biol., 83, 65, 10.1083/jcb.83.1.65 · DOI
  105. Ishiwata, 1997, Altered expression of insulin-like growth factor II receptor in human pancreatic cancer, Pancreas, 15, 367, 10.1097/00006676-199711000-00006 · DOI
  106. Jacobs, 2009, Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology, Nat. Protoc., 4, 58, 10.1038/nprot.2008.213 · DOI
  107. Jain, 2015, Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin, Colloids Surf. B: Biointerfaces, 134, 47, 10.1016/j.colsurfb.2015.06.027 · DOI
  108. Jefferis, 2009, Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action, Trends Pharmacol. Sci., 30, 356, 10.1016/j.tips.2009.04.007 · DOI
  109. Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch. Biochem. Biophys., 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
  110. Jeppsson, 1975, Characterization of alpha1-antitrypsin in the inclusion bodies from the liver in alpha 1-antitrypsin deficiency, N. Engl. J. Med., 293, 576, 10.1056/NEJM197509182931203 · DOI
  111. Kakkis, 1994, Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells, Protein Expr. Purif., 5, 225, 10.1006/prep.1994.1035 · DOI
  112. Kakkis, 2001, Enzyme-replacement therapy in mucopolysaccharidosis I, N. Engl. J. Med., 344, 182, 10.1056/NEJM200101183440304 · DOI
  113. Kaludov, 2001, Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity, J. Virol., 75, 6884, 10.1128/JVI.75.15.6884-6893.2001 · DOI
  114. Kamei, 2010, Definitive evidence that a single N-glycan among three glycans on inducible costimulator is required for proper protein trafficking and ligand binding, Biochem. Biophys. Res. Commun., 391, 557, 10.1016/j.bbrc.2009.11.098 · DOI
  115. Kang, 2018, Lysosomal targeting enhancement by conjugation of glycopeptides containing mannose-6-phosphate glycans derived from glyco-engineered yeast, Sci. Rep., 8, 8730, 10.1038/s41598-018-26913-4 · DOI
  116. Kaplan, 1977, Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts, Proc. Natl. Acad. Sci. U. S. A., 74, 2026, 10.1073/pnas.74.5.2026 · DOI · Paper page
  117. Karottki, 2020, Awakening dormant glycosyltransferases in CHO cells with CRISPRa, Biotechnol. Bioeng., 117, 593, 10.1002/bit.27199 · DOI
  118. Karpusas, 1998, The structure of human interferon-beta: implications for activity, Cell. Mol. Life Sci., 54, 1203, 10.1007/s000180050248 · DOI
  119. Kim, 2006, Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells, Mol. Cancer Ther., 5, 1723, 10.1158/1535-7163.MCT-05-0540 · DOI
  120. Kim, 2017, Comparative study of idursulfase beta and idursulfase in vitro and in vivo, J. Hum. Genet., 62, 167, 10.1038/jhg.2016.133 · DOI
  121. Kim, 2020, Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation, Mol. Carcinog., 59, 691, 10.1002/mc.23170 · DOI
  122. Kishnani, 2006, Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease, J. Pediatr., 149, 89, 10.1016/j.jpeds.2006.02.035 · DOI
  123. Kivisakk, 2000, Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis, Eur. J. Neurol., 7, 27, 10.1046/j.1468-1331.2000.00002.x · DOI
  124. Kolbeck, 2010, MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function, J. Allergy Clin. Immunol., 125
  125. Konrad, 1987, Assessment of the antigenic response in humans to a recombinant mutant interferon beta, J. Clin. Immunol., 7, 365, 10.1007/BF00917014 · DOI
  126. Krambeck, 2017, Model-based analysis of N-glycosylation in Chinese hamster ovary cells, PLoS One, 12, 10.1371/journal.pone.0175376 · DOI
  127. Kulkarni, 2021, The current landscape of nucleic acid therapeutics, Nat. Nanotechnol., 16, 630, 10.1038/s41565-021-00898-0 · DOI · Paper page
  128. Kumpel, 1994, Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity, Hum. Antibodies Hybridomas, 5, 143
  129. Kwon, 1997, Effect of glycosylation on the stability of alpha1-antitrypsin toward urea denaturation and thermal deactivation, Biochim. Biophys. Acta, 1335, 265, 10.1016/S0304-4165(96)00143-2 · DOI
  130. Lachmann, 2011, Enzyme replacement therapy for lysosomal storage diseases, Curr. Opin. Pediatr., 23, 588, 10.1097/MOP.0b013e32834c20d9 · DOI
  131. Largent, 1984, Carbohydrate-specific adhesion of alveolar macrophages to mannose-derivatized surfaces, J. Biol. Chem., 259, 1764, 10.1016/S0021-9258(17)43473-9 · DOI
  132. Larocca, 1989, Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser, J. Interf. Res., 9, S51
  133. Lassiter, 2021, Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects, Curr. Oncol., 28, 640, 10.3390/curroncol28010063 · DOI
  134. Lau, 2007, Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation, Cell, 129, 123, 10.1016/j.cell.2007.01.049 · DOI · Paper page
  135. Laube, 2009, Mannose-6-phosphate/insulin-like growth factor-II receptor in human melanoma cells: effect of ligands and antibodies on the receptor expression, Anticancer Res., 29, 1383
  136. Lee, 2003, A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease, Glycobiology, 13, 305, 10.1093/glycob/cwg034 · DOI
  137. Lee, 2015, Effects of N-glycosylation on protein conformation and dynamics: protein data Bank analysis and molecular dynamics simulation study, Sci. Rep., 5, 8926, 10.1038/srep08926 · DOI
  138. Li, 2001, Thrombocytopenia caused by the development of antibodies to thrombopoietin, Blood, 98, 3241, 10.1182/blood.V98.12.3241 · DOI
  139. Li, 2017, Modulating IgG effector function by Fc glycan engineering, Proc. Natl. Acad. Sci. U. S. A., 114, 3485, 10.1073/pnas.1702173114 · DOI
  140. Liang, 2020, A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering, Curr. Res. Biotechnol., 2, 22, 10.1016/j.crbiot.2020.01.001 · DOI
  141. Lis, 1993, Protein glycosylation. Structural and functional aspects, Eur. J. Biochem., 218, 1, 10.1111/j.1432-1033.1993.tb18347.x · DOI
  142. Liu, 2015, Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and fc-fusion proteins, J. Pharm. Sci., 104, 1866, 10.1002/jps.24444 · DOI · Paper page
  143. Liu, 2017, Impact of IgG fc-oligosaccharides on recombinant monoclonal antibody structure, stability, safety, and efficacy, Biotechnol. Prog., 33, 1173, 10.1002/btpr.2498 · DOI
  144. Liu, 2019, Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor, Sci. Rep., 9, 17830, 10.1038/s41598-019-54231-w · DOI
  145. Liu, 2020, N-glycosylation of PD-1 promotes binding of camrelizumab, EMBO Rep., 21, E51444, 10.15252/embr.202051444 · DOI
  146. Lopez-Sambrooks, 2016, Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells, Nat. Chem. Biol., 12, 1023, 10.1038/nchembio.2194 · DOI
  147. Lu, 2020, Development of therapeutic antibodies for the treatment of diseases, J. Biomed. Sci., 27, 1, 10.1186/s12929-019-0592-z · DOI
  148. Lu, 2022, PD-1 N58-glycosylation-dependent binding of monoclonal antibody cemiplimab for immune checkpoint therapy, Front. Immunol., 13
  149. Ludwig, 2003, Monoclonal antibody therapeutics and apoptosis, Oncogene, 22, 9097, 10.1038/sj.onc.1207104 · DOI
  150. Lundahl, 2021, Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies, RSC Chem. Biol., 2, 1004, 10.1039/D1CB00067E · DOI · Paper page
  151. Ma, 2004, CD28 T cell costimulatory receptor function is negatively regulated by N-linked carbohydrates, Biochem. Biophys. Res. Commun., 317, 60, 10.1016/j.bbrc.2004.03.012 · DOI
  152. Ma, 2020, Protein glycoengineering: an approach for improving protein properties, Front. Chem., 8, 622, 10.3389/fchem.2020.00622 · DOI
  153. Maack, 1979, Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review, Kidney Int., 16, 251, 10.1038/ki.1979.128 · DOI
  154. Macher, 2008, The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance, Biochim. Biophys. Acta, 1780, 75, 10.1016/j.bbagen.2007.11.003 · DOI · Paper page
  155. Madigan, 2016, Engineering AAV receptor footprints for gene therapy, Curr. Opin. Virol., 18, 89, 10.1016/j.coviro.2016.05.001 · DOI
  156. Madireddi, 2014, Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies, J. Exp. Med., 211, 1433, 10.1084/jem.20132687 · DOI
  157. Majewska, 2020, N-glycosylation of IgG and IgG-like recombinant therapeutic proteins: why is it important and how can we control it?, Annu Rev. Chem. Biomol. Eng., 11, 311, 10.1146/annurev-chembioeng-102419-010001 · DOI
  158. Markov, 2015, Multicomponent mannose-containing liposomes efficiently deliver RNA in murine immature dendritic cells and provide productive anti-tumour response in murine melanoma model, J. Control. Release, 213, 45, 10.1016/j.jconrel.2015.06.028 · DOI
  159. Martinez-Pomares, 2012, The mannose receptor, J. Leukoc. Biol., 92, 1177, 10.1189/jlb.0512231 · DOI
  160. Mary, 2019, Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes, FEBS J., 286, 4964, 10.1111/febs.15013 · DOI
  161. Mary, 2019, Molecular engineering of adeno-associated virus capsid improves its therapeutic gene transfer in murine models of Hemophilia and retinal degeneration, Mol. Pharm., 16, 4738, 10.1021/acs.molpharmaceut.9b00959 · DOI
  162. Matsuda, 2015, siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes, ACS Chem. Biol., 10, 1181, 10.1021/cb501028c · DOI
  163. Mccafferty, 2019, Vestronidase alfa: a review in mucopolysaccharidosis VII, BioDrugs, 33, 233, 10.1007/s40259-019-00344-7 · DOI
  164. Mereiter, 2019, Glycosylation in the era of cancer-targeted therapy: where are we heading?, Cancer Cell, 36, 6, 10.1016/j.ccell.2019.06.006 · DOI
  165. Meyer, 2022, Adeno-associated virus (AAV) cell entry: structural insights, Trends Microbiol., 30, 432, 10.1016/j.tim.2021.09.005 · DOI
  166. Mietzsch, 2014, Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans, J. Virol., 88, 2991, 10.1128/JVI.03371-13 · DOI
  167. Mimura, 2018, Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy, Protein Cell, 9, 47, 10.1007/s13238-017-0433-3 · DOI
  168. Minnelli, 2018, Selective induction of apoptosis in MCF7 cancer-cell by targeted liposomes functionalised with mannose-6-phosphate, J. Drug Target., 26, 242, 10.1080/1061186X.2017.1365873 · DOI
  169. Mitra, 2006, N-linked oligosaccharides as outfitters for glycoprotein folding, form and function, Trends Biochem. Sci., 31, 156, 10.1016/j.tibs.2006.01.003 · DOI · Paper page
  170. Mkhikian, 2011, Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis, Nat. Commun., 2, 334, 10.1038/ncomms1333 · DOI
  171. Molle, 2022, Nanoparticles for vaccine and gene therapy: overcoming the barriers to nucleic acid delivery, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 14, 10.1002/wnan.1809 · DOI
  172. Mondal, 2019, Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding, J. Biol. Chem., 294, 18465, 10.1074/jbc.RA119.011134 · DOI
  173. Moorkens, 2017, The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape, Front. Pharmacol., 8, 314, 10.3389/fphar.2017.00314 · DOI
  174. Morell, 1968, Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo, J. Biol. Chem., 243, 155, 10.1016/S0021-9258(18)99337-3 · DOI
  175. Morell, 1971, The role of sialic acid in determining the survival of glycoproteins in the circulation, J. Biol. Chem., 246, 1461, 10.1016/S0021-9258(19)76994-4 · DOI · Paper page
  176. Mossner, 2010, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity, Blood, 115, 4393, 10.1182/blood-2009-06-225979 · DOI
  177. Muenzer, 2002, Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report, Acta Paediatr. Suppl., 91, 98, 10.1111/j.1651-2227.2002.tb03118.x · DOI
  178. Muenzer, 2006, A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome), Genet. Med., 8, 465, 10.1097/01.gim.0000232477.37660.fb · DOI
  179. Muenzer, 2007, A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome), Mol. Genet. Metab., 90, 329, 10.1016/j.ymgme.2006.09.001 · DOI
  180. Narhi, 1991, The effect of carbohydrate on the structure and stability of erythropoietin, J. Biol. Chem., 266, 23022, 10.1016/S0021-9258(18)54457-4 · DOI
  181. Ng, 2010, Structural characterization of the dual glycan binding adeno-associated virus serotype 6, J. Virol., 84, 12945, 10.1128/JVI.01235-10 · DOI
  182. Nguyen, 2005, Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells, J. Immunol., 175, 228, 10.4049/jimmunol.175.1.228 · DOI
  183. Nimmerjahn, 2008, Anti-inflammatory actions of intravenous immunoglobulin, Annu. Rev. Immunol., 26, 513, 10.1146/annurev.immunol.26.021607.090232 · DOI
  184. Nimmerjahn, 2007, Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity, Proc. Natl. Acad. Sci. U. S. A., 104, 8433, 10.1073/pnas.0702936104 · DOI
  185. Nishida-Aoki, 2020, Altered biodistribution of deglycosylated extracellular vesicles through enhanced cellular uptake, J. Extracell. Vesicles, 9, 1713527, 10.1080/20013078.2020.1713527 · DOI
  186. Nishiyama, 2000, N-Glycans protect proteins from protease digestion through their binding affinities for aromatic amino acid residues, J. Biochem., 127, 427, 10.1093/oxfordjournals.jbchem.a022624 · DOI
  187. Nose, 1983, Biological significance of carbohydrate chains on monoclonal antibodies, Proc. Natl. Acad. Sci. U. S. A., 80, 6632, 10.1073/pnas.80.21.6632 · DOI
  188. Ogata, 2013, Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G, PLoS One, 8, 10.1371/journal.pone.0081448 · DOI
  189. Oh, 2015, Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases, BMB Rep., 48, 438, 10.5483/BMBRep.2015.48.8.101 · DOI
  190. Oh-Eda, 1990, O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity, J. Biol. Chem., 265, 11432, 10.1016/S0021-9258(19)38416-9 · DOI
  191. Okada, 2017, Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells, Cell Rep., 20, 1017, 10.1016/j.celrep.2017.07.027 · DOI
  192. Okamoto, 1991, Purification and characterization of three forms of differently glycosylated recombinant human granulocyte-macrophage colony-stimulating factor, Arch. Biochem. Biophys., 286, 562, 10.1016/0003-9861(91)90080-3 · DOI
  193. Okerblom, 2017, Biochemical, cellular, physiological, and pathological consequences of human loss of N-glycolylneuraminic acid, Chembiochem, 18, 1155, 10.1002/cbic.201700077 · DOI
  194. O’neil, 2007, High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history, J. Clin. Oncol., 25, 3644, 10.1200/JCO.2007.11.7812 · DOI
  195. Orange, 2006, Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, J. Allergy Clin. Immunol., 117, S525, 10.1016/j.jaci.2006.01.015 · DOI
  196. Padler-Karavani, 2008, Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease, Glycobiology, 18, 818, 10.1093/glycob/cwn072 · DOI
  197. Parenti, 2013, New strategies for the treatment of lysosomal storage diseases (review), Int. J. Mol. Med., 31, 11, 10.3892/ijmm.2012.1187 · DOI
  198. Parini, 2020, Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations, Int. J. Mol. Sci., 21, 10.3390/ijms21082975 · DOI
  199. Park, 2003, Rapid clearance of sialylated glycoproteins by the asialoglycoprotein receptor, J. Biol. Chem., 278, 4597, 10.1074/jbc.M210612200 · DOI
  200. Park, 2005, The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2,6GalNAc, Proc. Natl. Acad. Sci. U. S. A., 102, 17125, 10.1073/pnas.0508537102 · DOI

200 of 358 shown

Cited by

Sorted by citations

See all 67

Metadata

Authors
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E.
Venue
Biotechnology Advances
Publisher
Elsevier BV
Published
2023-10
Volume
67
Pages
108206
ISSN
0734-9750
DOI
10.1016/j.biotechadv.2023.108206
Cited by
67
References
26
Language
en
Licence
Funders
  • NIH
  • National Institute of General Medical Sciences (R35 GM119850)
  • Novo Nordisk Fonden (NNF20SA0066621)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review